Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (10064)	1/20/2004 2:55:07 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Ian, A lot depends on the market you are serving. Just look at the size of AMGN's sales force compared with a pharma with similar sales. If it's truly a niche market then 75 or so salespeople can do a decent job of penetrating the market. There just can't be that many radiation oncologists. Whether they can get the drug approved is still the key question. If you are going after primary care physicians then you need big numbers. Forest and (with luck) Sepracor are the only non-pharma that need a big sales force. Peter